More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction

Circulation

Volumn 91, Issue 11, 1995, Pages 2725-2732

  Smalling, Richard W ^a   Bode, Christoph ^b   Kalbfleisch, John ^c   Sen, Semi ^d   Limbourg, Peter ^e   Forycki, Florian ^f   Habib, Gabriel ^g   Feldman, Robert ^h   Hohnloser, Stefan ⁱ   Seals, Allen ^j  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c Cardiology of Tulsa Inc ^*

^d SAARLAND UNIVERSITY   (Germany)

^e Stadtkrankenhaus Worms ^*  (Germany)

^f Krankenhaus Neukoelln ^*  (Germany)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h Munroe Regional Med Center   (United States)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j University Medical Center   (United States)

more..

Author keywords

myocardial infarction; plasminogen activators; thrombolysis

Indexed keywords

ALTEPLASE; RECOMBINANT PLASMINOGEN ACTIVATOR; RETEPLASE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029066701     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.91.11.2725     Document Type: Article

References (25)

1. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
2. Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, Eisenberg M. Prehospital-initiated vs. hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Trial. JAMA. 1993;270:1211-1216.
3. Vogt A, von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol. 1993;21:1391-1395.
4. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction: evidence from the Team-3 study. Circulation. 1993;87:1829-1839.
5. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
6. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Kereiakes D, George B, Stack R, TAMI Study Group. Consequences of re-occlusion after successful reperfusion therapy in acute myocardial infarction. Circulation. 1990;82:781-791.
7. Dalen JE, Gore JM, Braunwald E, Borer J, Goldberg RJ, Passamani ER, Forman S, Knatterud G, TIMI Investigators. Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial. Am J Cardiol. 1988;62:179-185.
8. Martin U, Sponer G, Strein K. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. J Am Coll Cardiol. 1992;19:433-440.
9. Tebbe U, von Essen R, Smolarz A, Limbourg P, Rox J, Rustige J, Vogt A, Wagner J, Meyer-Sabellek W, Neuhaus KL. Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol. 1993;72:518-524.
10. Neuhaus KL, von Essen R, Vogt A, Tebbe U, Rustige J, Wagner HJ, Appel KF, Stienen U, Konig R, Meyer-Sabellek W. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German recombinant plasminogen activator study. J Am Coll Cardiol. 1994;24:55-60.
11. Linderer T, Schroder R, Arntz R, Heineking ML, Wunderlich W, Kohl K, Forycki F, Henzgen R, Wagner J. Prehospital thrombolysis: beneficial effects of very early treatment on infarct size and left ventricular function. J Am Coll Cardiol. 1993;22:1304-1310.
12. Karagounis L, Sorensen SG, Menlove RL, Moreno F, Anderson JL. Does Thrombolysis in Myocardial Infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. J Am Coll Cardiol. 1992;19:1-10.
13. Martin U, Fischer S, Kohnert U, Rudolph R, Sponer G, Stern A, Strein K. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. J Cardiovasc Pharmacol. 1991;18:111-119.
14. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76:142-154.
15. Topol E, Morris DC, Smalling RW, Schumacher RR, Taylor CR, Nishikawa A, Liberman HA, Collen D, Tufte ME, Grossbard EB, O'Neill WW. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. J Am Coll Cardiol. 1987;9:1205-1213.
16. Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol. 1989;14:1566-1569.
17. Smalling RW, Schumacher R, Morris D, Harder K, Fuentes F, Valentine RP, Battey LL, Merhige M, Pitts DE, Lieberman HA, Nishikawa A, Adyanthaya A, Hopkins A, Grossbard E. Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter randomized trial of two dosage regimens. J Am Coll Cardiol. 1990;15:915-921.
18. McKendall GR, Attubato MJ, Drew TM, Feit F, Sharaf BL, Thomas ES, Teichman S, McDonald MJ, Williams W. Safety and efficacy of a new regimen of intravenous recombinant tissue-type plasminogen activator potentially suitable for either prehospital or in-hospital administration. J Am Coll Cardiol. 1991;18:1774-1778.
19. Purvis J, McNeill A, Siddiqui R, Roberts M, McClements B, McEneaney D, Campbell N, Khan M, Webb S, Wilson C, Adgey J. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction. J Am Coll Cardiol. 1994;23:6-10.
20. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vlietstra RE, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1993;328:673-679.
21. Zijlstra F, DeBoer M, Hoorntje J, Reiffers S, Reiber J, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993;328:680-684.
22. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol. 1994;23: 993-1003.
23. Antman E, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation. 1994;90:1624-1630.
24. GUSTO IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
25. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol. 1993;22:381-389.